<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid/><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid">PMC6700635</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid-ver">PMC6700635.1</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaid">6700635</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaiid">6700635</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">31282416</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.3233/JAD-190152</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">JAD190152</article-id></all-ids><extracted-table><table-id>jad-70-jad190152-t001</table-id><table-label>Table 1</table-label><table-caption>CSF biomarker levels of AD patients</table-caption><table-wrap-foot>*Normal values: Aβ42 &gt; 580 pg/mL; Aβ42/Aβ40 &gt; 0.068; Tau &lt; 250 pg/mL; pTau (181) &lt; 37 pg/mL; Tau/Aβ42 &lt; 0.40; Aβ42/pTau &gt; 15.8.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="jad-70-jad190152-t001" orientation="portrait" position="float"><label>Table 1</label><caption><p>CSF biomarker levels of AD patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Aβ<sub>1–42</sub><sup>*</sup> (<italic toggle="yes">n</italic> = 17)</td><td rowspan="1" colspan="1">Aβ<sub>42</sub>/Aβ<sub>40</sub><sup>*</sup> (<italic toggle="yes">n</italic> = 14)</td><td rowspan="1" colspan="1">Tau<sup>*</sup> (<italic toggle="yes">n</italic> = 17)</td><td rowspan="1" colspan="1">pTau<sup>*</sup> (<italic toggle="yes">n</italic> = 17)</td><td rowspan="1" colspan="1">Tau/Aβ<sub>42</sub><sup>*</sup> (<italic toggle="yes">n</italic> = 17)</td><td rowspan="1" colspan="1">Aβ<sub>42</sub>/pTau<sup>*</sup> (<italic toggle="yes">n</italic> = 17)</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Mean</td><td rowspan="1" colspan="1">510.94</td><td rowspan="1" colspan="1">0.057</td><td rowspan="1" colspan="1">445.64</td><td rowspan="1" colspan="1">63.15</td><td rowspan="1" colspan="1">0.98</td><td rowspan="1" colspan="1">9.32</td></tr><tr><td rowspan="1" colspan="1">SD</td><td rowspan="1" colspan="1">215.00</td><td rowspan="1" colspan="1">0.021</td><td rowspan="1" colspan="1">246.80</td><td rowspan="1" colspan="1">24.36</td><td rowspan="1" colspan="1">0.52</td><td rowspan="1" colspan="1">6.28</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>Normal values: Aβ<sub>42</sub> &gt; 580 pg/mL; Aβ<sub>42</sub>/Aβ<sub>40</sub> &gt; 0.068; Tau &lt; 250 pg/mL; pTau (181) &lt; 37 pg/mL; Tau/Aβ<sub>42</sub> &lt; 0.40; Aβ<sub>42</sub>/pTau &gt; 15.8.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">CSF biomarker levels of AD patients</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><td/><td>Aβ1–42* (n = 17)</td><td>Aβ42/Aβ40* (n = 14)</td><td>Tau* (n = 17)</td><td>pTau* (n = 17)</td><td>Tau/Aβ42* (n = 17)</td><td>Aβ42/pTau* (n = 17)</td></tr></thead><tbody><tr><td>Mean</td><td>510.94</td><td>0.057</td><td>445.64</td><td>63.15</td><td>0.98</td><td>9.32</td></tr><tr><td>SD</td><td>215.00</td><td>0.021</td><td>246.80</td><td>24.36</td><td>0.52</td><td>6.28</td></tr></tbody></table></div>*Normal values: Aβ42 &gt; 580 pg/mL; Aβ42/Aβ40 &gt; 0.068; Tau &lt; 250 pg/mL; pTau (181) &lt; 37 pg/mL; Tau/Aβ42 &lt; 0.40; Aβ42/pTau &gt; 15.8.</transformed-table></extracted-table><extracted-table><table-id>jad-70-jad190152-t002</table-id><table-label>Table 2</table-label><table-caption>Demographics and clinical characteristics of all participants</table-caption><table-wrap-foot>HC, healthy controls; AD, patients with Alzheimer’s disease; SD, standard deviation; MoCA, Montreal cognitive assessment; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Examination. Data are expressed as mean±S.D, except for ApoE that is expressed as percentage of ɛ4 carriers. MMSE and MoCA: higher scores correspond to better performance. Concerning BLAD affected domains they showed the following ratios of impairment in AD participants: (Memory, 16/17; Executive, 12/17; Language, 7/17; Constructive, 4/17; Calculation, 3/17).</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="jad-70-jad190152-t002" orientation="portrait" position="float"><label>Table 2</label><caption><p>Demographics and clinical characteristics of all participants</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HC (<italic toggle="yes">n</italic> = 23)</td><td rowspan="1" colspan="1">AD (<italic toggle="yes">n</italic> = 17)</td><td rowspan="1" colspan="1"><italic toggle="yes">p</italic></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age±SD</td><td rowspan="1" colspan="1">63.43±7.53</td><td rowspan="1" colspan="1">66.47±6.63</td><td rowspan="1" colspan="1">0.193</td></tr><tr><td rowspan="1" colspan="1">Female/Male (ratio)</td><td rowspan="1" colspan="1">11/12 (0.92)</td><td rowspan="1" colspan="1">8/9 (0.89)</td><td rowspan="1" colspan="1">0.962</td></tr><tr><td rowspan="1" colspan="1">Education (y)</td><td rowspan="1" colspan="1">9.3±5.93</td><td rowspan="1" colspan="1">8.95±5.20</td></tr><tr><td rowspan="1" colspan="1">MMSE</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">23,1±2.97</td></tr><tr><td rowspan="1" colspan="1">MoCA</td><td rowspan="1" colspan="1">25.83±3.31</td><td rowspan="1" colspan="1">14.47±4.51</td><td rowspan="1" colspan="1"><bold>&lt;0.001<sup><bold>*</bold></sup></bold></td></tr><tr><td rowspan="1" colspan="1">CDR</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">–</td></tr><tr><td rowspan="1" colspan="1">ApoE <italic toggle="yes">ɛ</italic>4 (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">44%</td></tr></tbody></table><table-wrap-foot><p>HC, healthy controls; AD, patients with Alzheimer’s disease; SD, standard deviation; MoCA, Montreal cognitive assessment; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Examination. Data are expressed as mean±S.D, except for ApoE that is expressed as percentage of <italic toggle="yes">ɛ</italic>4 carriers. MMSE and MoCA: higher scores correspond to better performance. Concerning BLAD affected domains they showed the following ratios of impairment in AD participants: (Memory, 16/17; Executive, 12/17; Language, 7/17; Constructive, 4/17; Calculation, 3/17).</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographics and clinical characteristics of all participants</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><td/><td>HC (n = 23)</td><td>AD (n = 17)</td><td>p</td></tr></thead><tbody><tr><td>Age±SD</td><td>63.43±7.53</td><td>66.47±6.63</td><td>0.193</td></tr><tr><td>Female/Male (ratio)</td><td>11/12 (0.92)</td><td>8/9 (0.89)</td><td>0.962</td></tr><tr><td>Education (y)</td><td>9.3±5.93</td><td>8.95±5.20</td></tr><tr><td>MMSE</td><td/><td>23,1±2.97</td></tr><tr><td>MoCA</td><td>25.83±3.31</td><td>14.47±4.51</td><td>&lt;0.001*</td></tr><tr><td>CDR</td><td>0</td><td>1</td><td>–</td></tr><tr><td>ApoE ɛ4 (%)</td><td/><td>44%</td></tr></tbody></table></div>HC, healthy controls; AD, patients with Alzheimer’s disease; SD, standard deviation; MoCA, Montreal cognitive assessment; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Examination. Data are expressed as mean±S.D, except for ApoE that is expressed as percentage of ɛ4 carriers. MMSE and MoCA: higher scores correspond to better performance. Concerning BLAD affected domains they showed the following ratios of impairment in AD participants: (Memory, 16/17; Executive, 12/17; Language, 7/17; Constructive, 4/17; Calculation, 3/17).</transformed-table></extracted-table><extracted-table><table-id>jad-70-jad190152-t003</table-id><table-label>Table 3</table-label><table-caption>FA, MD, RD. and DA whole-brain values (mean±SD), for all participants</table-caption><table-wrap-foot>HC, healthy controls; AD, patients with Alzheimer’s disease; SD, standard deviation; FA, fractional anisotropy; MD, mean diffusivity; RD, radial diffusivity; DA, axial diffusivity.*p-values &lt;0.05 were considered statistically significant (corrected for multiple comparisons by using post-hoc Bonferroni correction for the number of metrics considered).</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="jad-70-jad190152-t003" orientation="portrait" position="float"><label>Table 3</label><caption><p>FA, MD, RD. and DA whole-brain values (mean±SD), for all participants</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1">DTI metric (whole skeleton)</td><td rowspan="1" colspan="1">HC (<italic toggle="yes">n</italic> = 23)</td><td rowspan="1" colspan="1">AD (<italic toggle="yes">n</italic> = 17)</td><td rowspan="1" colspan="1"><italic toggle="yes">p</italic></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">FA</td><td rowspan="1" colspan="1">0.434±0.024</td><td rowspan="1" colspan="1">0.441±0.018</td><td rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">MD (×10<sup>3</sup> mm<sup>2</sup>/s)</td><td rowspan="1" colspan="1">0.730±0.031</td><td rowspan="1" colspan="1">0.716±0.047</td><td rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">RD (×10<sup>3</sup> mm<sup>2</sup>/s)</td><td rowspan="1" colspan="1">0.550±0.029</td><td rowspan="1" colspan="1">0.553±0.045</td><td rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">DA (×10<sup>3</sup> mm<sup>2</sup>/s)</td><td rowspan="1" colspan="1">1.09±0.040</td><td rowspan="1" colspan="1">1.04±0.058</td><td rowspan="1" colspan="1"><bold>0.016<sup><bold>*</bold></sup></bold></td></tr></tbody></table><table-wrap-foot><p>HC, healthy controls; AD, patients with Alzheimer’s disease; SD, standard deviation; FA, fractional anisotropy; MD, mean diffusivity; RD, radial diffusivity; DA, axial diffusivity.<sup>*</sup><italic toggle="yes">p</italic>-values &lt;0.05 were considered statistically significant (corrected for multiple comparisons by using <italic toggle="yes">post-hoc</italic> Bonferroni correction for the number of metrics considered).</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">FA, MD, RD. and DA whole-brain values (mean±SD), for all participants</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><td>DTI metric (whole skeleton)</td><td>HC (n = 23)</td><td>AD (n = 17)</td><td>p</td></tr></thead><tbody><tr><td>FA</td><td>0.434±0.024</td><td>0.441±0.018</td><td>1.00</td></tr><tr><td>MD (×103 mm2/s)</td><td>0.730±0.031</td><td>0.716±0.047</td><td>1.00</td></tr><tr><td>RD (×103 mm2/s)</td><td>0.550±0.029</td><td>0.553±0.045</td><td>1.00</td></tr><tr><td>DA (×103 mm2/s)</td><td>1.09±0.040</td><td>1.04±0.058</td><td>0.016*</td></tr></tbody></table></div>HC, healthy controls; AD, patients with Alzheimer’s disease; SD, standard deviation; FA, fractional anisotropy; MD, mean diffusivity; RD, radial diffusivity; DA, axial diffusivity.*p-values &lt;0.05 were considered statistically significant (corrected for multiple comparisons by using post-hoc Bonferroni correction for the number of metrics considered).</transformed-table></extracted-table><extracted-table><table-id>jad-70-jad190152-t004</table-id><table-label>Table 4</table-label><table-caption>White matter tracts’ FA correlated with INL thickness in patients with Alzheimer’s disease (n = 17), with the largest effects in terms of spatial extent</table-caption><table-wrap-foot>*p-values &lt;0.05 were considered statistically significant (corrected for multiple comparisons by controlling for family-wise error rates). **Percentage of statistically significant voxels within each labelled tract.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="jad-70-jad190152-t004" orientation="portrait" position="float"><label>Table 4</label><caption><p>White matter tracts’ FA correlated with INL thickness in patients with Alzheimer’s disease (<italic toggle="yes">n</italic> = 17), with the largest effects in terms of spatial extent</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="justify" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1">WM tracts</td><td rowspan="1" colspan="1"><italic toggle="yes">p</italic><sup>*</sup></td><td rowspan="1" colspan="1">Significant voxels (%)<sup>**</sup></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Body of corpus callosum</td><td rowspan="1" colspan="1">0.033</td><td rowspan="1" colspan="1">58.67</td></tr><tr><td rowspan="1" colspan="1">Tapetum R</td><td rowspan="1" colspan="1">0.042</td><td rowspan="1" colspan="1">43.24</td></tr><tr><td rowspan="1" colspan="1">Posterior corona radiata R</td><td rowspan="1" colspan="1">0.037</td><td rowspan="1" colspan="1">39.07</td></tr><tr><td rowspan="1" colspan="1">Retrolenticular part of internal capsule R</td><td rowspan="1" colspan="1">0.040</td><td rowspan="1" colspan="1">33.12</td></tr><tr><td rowspan="1" colspan="1">Posterior thalamic radiation (include optic radiation) L</td><td rowspan="1" colspan="1">0.043</td><td rowspan="1" colspan="1">31.67</td></tr><tr><td rowspan="1" colspan="1">Superior corona radiata R</td><td rowspan="1" colspan="1">0.032</td><td rowspan="1" colspan="1">30.60</td></tr><tr><td rowspan="1" colspan="1">Anterior corona radiata R</td><td rowspan="1" colspan="1">0.028</td><td rowspan="1" colspan="1">28.81</td></tr><tr><td rowspan="1" colspan="1">Splenium of corpus callosum</td><td rowspan="1" colspan="1">0.035</td><td rowspan="1" colspan="1">26.91</td></tr><tr><td rowspan="1" colspan="1">Cingulum (cingulate gyrus) L</td><td rowspan="1" colspan="1">0.039</td><td rowspan="1" colspan="1">22.76</td></tr><tr><td rowspan="1" colspan="1">Superior longitudinal fasciculus R</td><td rowspan="1" colspan="1">0.043</td><td rowspan="1" colspan="1">21.11</td></tr><tr><td rowspan="1" colspan="1">Superior corona radiata L</td><td rowspan="1" colspan="1">0.037</td><td rowspan="1" colspan="1">20.35</td></tr><tr><td rowspan="1" colspan="1">Genu of corpus callosum</td><td rowspan="1" colspan="1">0.035</td><td rowspan="1" colspan="1">19.11</td></tr><tr><td rowspan="1" colspan="1">Posterior corona radiata L</td><td rowspan="1" colspan="1">0.034</td><td rowspan="1" colspan="1">18.16</td></tr><tr><td rowspan="1" colspan="1">Cingulum (cingulate gyrus) R</td><td rowspan="1" colspan="1">0.035</td><td rowspan="1" colspan="1">16.99</td></tr><tr><td rowspan="1" colspan="1">Fornix (cres)/Stria terminalis L</td><td rowspan="1" colspan="1">0.043</td><td rowspan="1" colspan="1">14.29</td></tr><tr><td rowspan="1" colspan="1">Posterior thalamic radiation (include optic radiation) R</td><td rowspan="1" colspan="1">0.041</td><td rowspan="1" colspan="1">11.85</td></tr><tr><td rowspan="1" colspan="1">Posterior limb of internal capsule R</td><td rowspan="1" colspan="1">0.041</td><td rowspan="1" colspan="1">8.51</td></tr><tr><td rowspan="1" colspan="1">Anterior corona radiata L</td><td rowspan="1" colspan="1">0.037</td><td rowspan="1" colspan="1">8.49</td></tr><tr><td rowspan="1" colspan="1">Superior longitudinal fasciculus L</td><td rowspan="1" colspan="1">0.043</td><td rowspan="1" colspan="1">6.17</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup><italic toggle="yes">p</italic>-values &lt;0.05 were considered statistically significant (corrected for multiple comparisons by controlling for family-wise error rates). <sup>**</sup>Percentage of statistically significant voxels within each labelled tract.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">White matter tracts’ FA correlated with INL thickness in patients with Alzheimer’s disease (n = 17), with the largest effects in terms of spatial extent</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><colgroup><col align="justify"/></colgroup><thead valign="top"><tr><td>WM tracts</td><td>p*</td><td>Significant voxels (%)**</td></tr></thead><tbody><tr><td>Body of corpus callosum</td><td>0.033</td><td>58.67</td></tr><tr><td>Tapetum R</td><td>0.042</td><td>43.24</td></tr><tr><td>Posterior corona radiata R</td><td>0.037</td><td>39.07</td></tr><tr><td>Retrolenticular part of internal capsule R</td><td>0.040</td><td>33.12</td></tr><tr><td>Posterior thalamic radiation (include optic radiation) L</td><td>0.043</td><td>31.67</td></tr><tr><td>Superior corona radiata R</td><td>0.032</td><td>30.60</td></tr><tr><td>Anterior corona radiata R</td><td>0.028</td><td>28.81</td></tr><tr><td>Splenium of corpus callosum</td><td>0.035</td><td>26.91</td></tr><tr><td>Cingulum (cingulate gyrus) L</td><td>0.039</td><td>22.76</td></tr><tr><td>Superior longitudinal fasciculus R</td><td>0.043</td><td>21.11</td></tr><tr><td>Superior corona radiata L</td><td>0.037</td><td>20.35</td></tr><tr><td>Genu of corpus callosum</td><td>0.035</td><td>19.11</td></tr><tr><td>Posterior corona radiata L</td><td>0.034</td><td>18.16</td></tr><tr><td>Cingulum (cingulate gyrus) R</td><td>0.035</td><td>16.99</td></tr><tr><td>Fornix (cres)/Stria terminalis L</td><td>0.043</td><td>14.29</td></tr><tr><td>Posterior thalamic radiation (include optic radiation) R</td><td>0.041</td><td>11.85</td></tr><tr><td>Posterior limb of internal capsule R</td><td>0.041</td><td>8.51</td></tr><tr><td>Anterior corona radiata L</td><td>0.037</td><td>8.49</td></tr><tr><td>Superior longitudinal fasciculus L</td><td>0.043</td><td>6.17</td></tr></tbody></table></div>*p-values &lt;0.05 were considered statistically significant (corrected for multiple comparisons by controlling for family-wise error rates). **Percentage of statistically significant voxels within each labelled tract.</transformed-table></extracted-table></extracted-tables-set>